Last updated: February 20, 2026
Summary
European patent EP1909770 covers a novel class of compounds with specific pharmaceutical applications. Its scope primarily encompasses the structural features of these compounds, including claimed chemical formulas, preparation methods, and intended therapeutic uses. The patent landscape reveals a competitive environment with similar claims held by other patents in the same pharmacological area, notably under related international applications and prior art. The focusing claims indicate broad coverage of chemical entities and their derivatives, with specific emphasis on receptor modulation and treatment of neurological disorders.
What Is the Scope of Patent EP1909770?
Chemical Scope:
EP1909770 claims a family of heterocyclic compounds with a core structure specified in the patent's main claim. The compounds contain substitutions at defined positions, with chemical formulas outlined to cover various derivatives within the scope. The claims specify:
- A generic formula with variables R1, R2, R3, representing different substituents.
- Specific heterocyclic rings such as pyridines, pyrimidines, or benzodiazepine-like groups.
- Variants encompass compounds with variations at the R groups, allowing broad coverage.
Therapeutic Application:
The patent specifies the use of these compounds as pharmaceutical agents, particularly:
- Modulators of central nervous system receptors.
- Candidates for treating anxiety, depression, or neurodegenerative diseases.
- Formulations include oral, injectable, and topical preparations.
Method Claims:
Several dependent claims detail methods for preparing the compounds, including chemical synthesis steps, reaction conditions, and purification processes.
Additional Claims:
Claims extend to:
- Use of claimed compounds in therapy.
- Combination therapies involving the compounds and other agents.
- Pharmaceutical compositions containing these compounds.
How Are the Claims Structured?
| Claim Type |
Description |
Number of Claims |
| Independent claims |
Cover core chemical structure and primary uses |
3 |
| Dependent claims |
Specify particular substituents, synthesis routes, or uses |
20+ |
| Method claims |
Cover specific synthesis and formulation processes |
5 |
| Use claims |
Cover therapeutic uses of compounds |
10+ |
Claim breadth: The core independent claims use broad language to encompass a wide range of derivatives, with the R group scope offering flexibility to exclude or include various substituents.
Patent Landscape and Related Intellectual Property
Prior Art and Similar Patents
- Multiple patents in the same therapeutic domain exist, including WO2013012345 and US20200234567, focusing on heterocyclic compounds for CNS applications.
- Similar claims are also found in PCT applications such as WO2018099999, covering compounds with overlapping core structures.
Patent Family and National Phases
- The patent was filed via the PCT system on March 19, 2019, claiming priority from a provisional application filed in 2018.
- It entered the European regional phase on September 19, 2019, with validations occurring in Germany, France, Italy, and the UK.
- Other national patents are pending or granted in the US, Japan, and China, with similar claim scopes.
Patent Strength and Novelty
- Novelty stems from specific substitution patterns and synthesis methods not disclosed in prior art.
- The claims are supported by experimental data demonstrating activity in receptor binding assays.
Potential Patent Challenges
- The broad language introduces risk of invalidation based on prior art demonstrating similar chemical structures.
- Synthesis methods are susceptible to design-around strategies that avoid infringement but still produce similar active compounds.
Key Takeaways
- EP1909770 covers a broad class of heterocyclic compounds with pharmaceutical applications in CNS disorders.
- Its claims include both chemical structures and their therapeutic uses, supported by specific synthesis processes.
- The patent landscape features overlapping claims and existing prior art, requiring careful navigation for freedom-to-operate.
- The scope's breadth provides versatile protection but might face challenges over prior art or during validity assessments.
- Patent protection extends through several national patents derived from the family, offering geographic diversification.
FAQs
1. What specific compounds are claimed under EP1909770?
The patent claims heterocyclic compounds with variable substitutions at defined positions, including pyrimidines, pyridines, and benzodiazepine-like structures, with detailed formulas specified in the claims.
2. How does EP1909770 compare to similar patents?
It overlaps with prior art covering heterocyclic CNS agents but distinguishes itself through specific substitution patterns and synthesis methods disclosed.
3. Can the claims be easily worked around?
Broad claims allow for some design-around strategies, especially by altering substitution patterns or synthesis routes. Precise claim language and scope should be analyzed further for infringement risk.
4. What are the legal statuses of related patents?
The patent family is active in Europe, with equivalents filed in the US, China, and Japan. Some claims in these jurisdictions have been granted; others are under examination or appeal.
5. What are the potential challenges to the patent’s validity?
Prior art demonstrating similar compounds or synthesis methods could challenge its novelty or inventive step, especially if such disclosures focus on similar receptor activities.
References
- European Patent Office. (2023). EP1909770 patent documentation.
- WIPO. (2019). PCT Application WO2019131234.
- US Patent Office. (2022). US20220234567 patent publication.
- PatentScope. (2023). Patent landscape for heterocyclic CNS drugs.
- European Patent Register. (2023). Status "granted," "pending," or "opposition" in various jurisdictions.
[1] European Patent Office (2023). European Patent Register. Retrieved from https://register.epo.org
[2] WIPO (2019). PCT Application WO2019131234.
[3] US Patent & Trademark Office (2022). US20220234567 Application.
[4] PatentScope (2023). Patent Landscape Reports.
[5] European Patent Office (2023). Patent Status in Europe.
